$25.84
1.26%
Nasdaq, Nov 19, 04:00 pm EST. Closed.
ISIN
US92686J1060
Symbol
VKTX

Viking Therapeutics, Inc. Stock price

$25.84
+0.79 3.15% 1M
-2.56 9.01% 6M
-9.34 26.55% YTD
-10.20 28.30% 1Y
+14.07 119.54% 3Y
+20.20 358.16% 5Y
+24.68 2,127.59% 10Y
+16.88 188.39% 20Y
Nasdaq, Closing price Thu, Nov 19 2026
-0.33 1.26%
ISIN
US92686J1060
Symbol
VKTX
Industry

AI Insights on Viking Therapeutics, Inc. Insights AI Insights on Viking Therapeutics, Inc.

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Is Viking Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,085 stocks worldwide.

Key metrics

Basic
Market capitalization
$3.3b
Enterprise Value
$2.8b
Net debt
positive
Cash
$501.7m
Shares outstanding
116.7m
Valuation
P/E
negative
P/S | estimate
- | -
EV/Sales | estimate
- | -
EV/FCF | ex SBC
negative | negative
P/B
8.1
Financial Health
Equity Ratio
89.3%
Return on Equity
-56.3%
ROCE
-135.9%
ROIC
-
Debt/Equity
0.0
Share-Based Compensation & Dilution
SBC | % of Revenue
$37.4m | -
SBC as % of FCF
-
SBC Growth 1Y
-5.5%
Share Count Growth 1Y
3.8%
Shareholder Yield
-3.8%
Financials
Revenue | estimate
$0.0 | $0.0
EBITDA
-
EBIT
$-560.0m
Net Income
$-534.8m
Free Cash Flow | ex SBC
$-418.4m | $-455.8m
Growth
Revenue | estimate
- | -
EBITDA
-
EBIT
-163.1%
Net Income
-211.7%
Free Cash Flow
-174.3%
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow | ex SBC
- | -
More
EPS
$-4.6
FCF per Share
$-3.6
Short interest
19.9%
Employees
59
Rev per Employee
$0.0

Viking Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

27 Analysts have issued a Viking Therapeutics, Inc. forecast:

24x Buy
89%
3x Hold
11%

Analyst Opinions

27 Analysts have issued a Viking Therapeutics, Inc. forecast:

Buy
89%
Hold
11%

Viking Therapeutics, Inc. Events

Past Events
NOV
18
Jefferies London Healthcare Conference
2 days ago
OCT
28
Q3 2026 Earnings Call
23 days ago
SEP
22
Special Call - Viking Therapeutics, Inc.
about 2 months ago
SEP
14
Morgan Stanley 24th Annual Global Healthcare Conference
2 months ago
JUL
29
Q2 2026 Earnings Call
4 months ago
JUN
4
Jefferies Global Healthcare Conference 2026
6 months ago
APR
29
Q1 2026 Earnings Call
7 months ago
MAR
10
Leerink Global Healthcare Conference 2026
8 months ago
FEB
11
Q4 2025 Earnings Call
9 months ago
JAN
12
44th Annual J.P. Morgan Healthcare Conference
10 months ago
NOV
19
Jefferies London Healthcare Conference 2025
about one year ago
OCT
22
Q3 2025 Earnings Call
about one year ago

Financial data from Viking Therapeutics, Inc.

Jun '26
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 51 51
12% 12%
-
- Research and Development Expense 509 509
228% 228%
-
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -560 -560
163% 163%
-
Net Profit -535 -535
212% 212%
-

In millions USD.

Don't miss a Thing! We will send you all news about Viking Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Viking Therapeutics, Inc. Stock News

Neutral
PRNewsWire
●
5 days ago
VENTURE Analysis Finds 74% of Participants Receiving Subcutaneous VK2735 Improved by at Least One BMI Category after 13 Weeks VK2735 Treatment Led to Improvement Across Multiple Cardiometabolic Markers SAN DIEGO, Nov. 15, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic ...
Neutral
PRNewsWire
●
11 days ago
Poster Presentations Highlight Baseline Characteristics from the Phase 3 VANQUISH-2 Trial of Subcutaneous VK2735 and the Impact of VK2735 on Obesity Severity and Cardiometabolic Parameters in the Phase 2 VENTURE Study SAN DIEGO, Nov. 9, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapi...
More Viking Therapeutics, Inc. News

Company Profile

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapies for patients suffering from metabolic and endocrine disorders. The company's clinical program VK5211, treats patients recovering from non-elective hip fracture surgery. It also specializes in development of VK2809 and VK0214. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Head office United States
CEO Dr. Lian
Employees 59
Founded 2012
Website vikingtherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today